{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"No of participants who experience DLTs at ibrutinib 560mg"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"No of participants who do not experience DLTs at ibrutinib 560mg"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Will be descriptive and will be reported in tabular format with the appropriate summary statistics (count and percentage). In the dose-finding portion, the number of DLTs identified among the DLT-evaluable subjects will be listed and summarized by dose level. The safety variables will be listed and summarized for (1) subjects in the dose-finding portion, (2) subjects in the DEC, and (3) all subjects in the study.","groups":[{"description":"Each participant in the dose-finding cohort must have completed at least cycle 1 (or 21 days) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). Starting dose of ibrutinib is 560 mg PO.\n\nRP2D is dose level which DLT rate is less than 33%.","id":"OG000","title":"Dose-finding Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who receive study treatment","reportingStatus":"POSTED","timeFrame":"Up to 21 days","title":"Recommended Phase II Dose (RP2D) of Ibrutinib in Combination With Chemotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}